Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. New research ...
Nov 13, 2013
0
0
Amsterdam, The Netherlands: First results from a phase III clinical trial of the combination drug, T-DM1, show that it significantly improves the length of time before the disease worsens in women with advanced HER2 positive ...
Sep 27, 2013
0
0
A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.
May 2, 2013
0
0
Researchers at Fox Chase Cancer Center have identified a host of small molecules critical to metabolism in cells of triple-negative breast cancer—one of the least understood groups of breast cancer. These molecules, called ...
Apr 9, 2013
0
0
(Medical Xpress)—Bioengineering researchers at University of California, Santa Barbara have found that changing the shape of chemotherapy drug nanoparticles from spherical to rod-shaped made them up to 10,000 times more ...
Feb 27, 2013
0
0
Patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy with the addition of a phosphatidylinositol-3 kinase inhibitor to their treatment regimens.
Jan 23, 2013
0
0
(HealthDay)—For patients with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer, one year of adjuvant trastuzumab should remain the standard of care, according to a study presented at the ...
Dec 7, 2012
0
0
Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin), Yale School of Medicine researchers report ...
Nov 14, 2012
0
0
(HealthDay)—For women with operable breast cancer, moderate immunohistochemical expression of human epidermal growth factor receptor (HER)-2 (2+) without amplification of HER-2 (HER-2 2+/HER-2−) is an adverse prognostic ...
Oct 30, 2012
0
0
New studies that advance understanding of the optimal duration of therapy with the targeted cancer drug trastuzumab were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Oct 1, 2012
0
0
